New drug combo aims to boost cervical cancer treatment
NCT ID NCT07232654
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial is testing whether adding an experimental immune therapy (Iparomlimab/Tuvonralimab) to standard chemoradiation can improve outcomes for 30 women with locally advanced cervical cancer. The treatment targets two immune checkpoints to help the body fight cancer. The main goal is to see if more patients are cancer-free after two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Iparomlimab/Tuvonralimab (a combination of two immune-boosting antibodies) plus chemotherapy (cisplatin) and radiation therapy
- What this could lead to
- If successful, this could offer a new treatment option that improves long-term control of locally advanced cervical cancer.
- What could go wrong
- This is an early Phase 2 trial with only 30 participants, so results may not apply to everyone. The combination therapy may cause significant side effects, and it is not yet known if it works better than standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CERVICAL CANCERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Center/Cancer Hospital
RECRUITINGBeijing, China
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.